Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method

Linnea M. Baudhuin; Stacy J. Hartman; John F. O'Brien; Irene Meissner; Robert S. Galen; Jennie N. Ward; Scott M. Hogen; Earl L. Branum; Joseph P. McConnell

doi:10.1016/j.clinbiochem.2004.02.001

Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method

Linnea M. Baudhuin, Stacy J. Hartman, John F. O'Brien, Irene Meissner, Robert S. Galen, Jennie N. Ward, Scott M. Hogen, Earl L. Branum, Joseph P. McConnell

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Objectives: Elevated plasma lipoprotein(a) [Lp(a)] is a significant risk factor for vascular disease. Standardization of Lp(a) mass measurement is complicated by the heterogeneity of apolipoprotein(a) [apo(a)]. We investigated whether Lp(a) cholesterol measurement, which is not influenced by apo(a) size, is a viable alternative to measuring Lp(a) mass. Design and methods: Plasma Lp(a) cholesterol was measured electrophoretically, with and without ultracentrifugation, and results were compared to each other and to immunoturbidimetrically measured Lp(a) mass in 470 subjects. Results: Ultracentrifuged and whole plasma Lp(a) cholesterol levels demonstrated high correlation (R = 0.964). All samples with detectable (≥2.0 mg/dl) Lp(a) cholesterol had Lp(a) mass >30 mg/dl (the clinically relevant cutpoint), while 59 samples with Lp(a) mass >30 mg/dl did not have detectable Lp(a) cholesterol. Conclusions: Lp(a) cholesterol can be measured in whole plasma without interference from VLDL lipoproteins. The relative clinical merits of measuring Lp(a) cholesterol vs. Lp(a) mass or both in combination deserves investigation.

Original language	English (US)
Pages (from-to)	481-488
Number of pages	8
Journal	Clinical Biochemistry
Volume	37
Issue number	6 SPEC. ISS.
DOIs	https://doi.org/10.1016/j.clinbiochem.2004.02.001
State	Published - Jun 2004

Keywords

Apolipoprotein(a)
Lipoprotein(a)
Lp(a) cholesterol
Lp(a) mass
Ultracentrifugation

ASJC Scopus subject areas

Clinical Biochemistry

Access to Document

10.1016/j.clinbiochem.2004.02.001

Cite this

Baudhuin, L. M., Hartman, S. J., O'Brien, J. F., Meissner, I., Galen, R. S., Ward, J. N., Hogen, S. M., Branum, E. L., & McConnell, J. P. (2004). Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method. Clinical Biochemistry, 37(6 SPEC. ISS.), 481-488. https://doi.org/10.1016/j.clinbiochem.2004.02.001

Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method. / Baudhuin, Linnea M.; Hartman, Stacy J.; O'Brien, John F. et al.
In: Clinical Biochemistry, Vol. 37, No. 6 SPEC. ISS., 06.2004, p. 481-488.

Research output: Contribution to journal › Article › peer-review

Baudhuin, LM, Hartman, SJ, O'Brien, JF, Meissner, I, Galen, RS, Ward, JN, Hogen, SM, Branum, EL & McConnell, JP 2004, 'Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method', Clinical Biochemistry, vol. 37, no. 6 SPEC. ISS., pp. 481-488. https://doi.org/10.1016/j.clinbiochem.2004.02.001

@article{31b6dfb14a6d4e4596e06f0e4313d0a7,

title = "Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method",

abstract = "Objectives: Elevated plasma lipoprotein(a) [Lp(a)] is a significant risk factor for vascular disease. Standardization of Lp(a) mass measurement is complicated by the heterogeneity of apolipoprotein(a) [apo(a)]. We investigated whether Lp(a) cholesterol measurement, which is not influenced by apo(a) size, is a viable alternative to measuring Lp(a) mass. Design and methods: Plasma Lp(a) cholesterol was measured electrophoretically, with and without ultracentrifugation, and results were compared to each other and to immunoturbidimetrically measured Lp(a) mass in 470 subjects. Results: Ultracentrifuged and whole plasma Lp(a) cholesterol levels demonstrated high correlation (R = 0.964). All samples with detectable (≥2.0 mg/dl) Lp(a) cholesterol had Lp(a) mass >30 mg/dl (the clinically relevant cutpoint), while 59 samples with Lp(a) mass >30 mg/dl did not have detectable Lp(a) cholesterol. Conclusions: Lp(a) cholesterol can be measured in whole plasma without interference from VLDL lipoproteins. The relative clinical merits of measuring Lp(a) cholesterol vs. Lp(a) mass or both in combination deserves investigation.",

keywords = "Apolipoprotein(a), Lipoprotein(a), Lp(a) cholesterol, Lp(a) mass, Ultracentrifugation",

author = "Baudhuin, {Linnea M.} and Hartman, {Stacy J.} and O'Brien, {John F.} and Irene Meissner and Galen, {Robert S.} and Ward, {Jennie N.} and Hogen, {Scott M.} and Branum, {Earl L.} and McConnell, {Joseph P.}",

note = "Funding Information: We thank Dr. Allan S. Jaffe (Mayo Clinic, Rochester, MN) for critical review of this manuscript. This work was supported in part by a grant from the National Institutes of Health, grant # NSO6663.",

year = "2004",

month = jun,

doi = "10.1016/j.clinbiochem.2004.02.001",

language = "English (US)",

volume = "37",

pages = "481--488",

journal = "Clinical Biochemistry",

issn = "0009-9120",

publisher = "Elsevier Inc.",

number = "6 SPEC. ISS.",

}

TY - JOUR

T1 - Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation

T2 - Comparison with an immunoturbidimetric lipoprotein(a) method

AU - Baudhuin, Linnea M.

AU - Hartman, Stacy J.

AU - O'Brien, John F.

AU - Meissner, Irene

AU - Galen, Robert S.

AU - Ward, Jennie N.

AU - Hogen, Scott M.

AU - Branum, Earl L.

AU - McConnell, Joseph P.

N1 - Funding Information: We thank Dr. Allan S. Jaffe (Mayo Clinic, Rochester, MN) for critical review of this manuscript. This work was supported in part by a grant from the National Institutes of Health, grant # NSO6663.

PY - 2004/6

Y1 - 2004/6

N2 - Objectives: Elevated plasma lipoprotein(a) [Lp(a)] is a significant risk factor for vascular disease. Standardization of Lp(a) mass measurement is complicated by the heterogeneity of apolipoprotein(a) [apo(a)]. We investigated whether Lp(a) cholesterol measurement, which is not influenced by apo(a) size, is a viable alternative to measuring Lp(a) mass. Design and methods: Plasma Lp(a) cholesterol was measured electrophoretically, with and without ultracentrifugation, and results were compared to each other and to immunoturbidimetrically measured Lp(a) mass in 470 subjects. Results: Ultracentrifuged and whole plasma Lp(a) cholesterol levels demonstrated high correlation (R = 0.964). All samples with detectable (≥2.0 mg/dl) Lp(a) cholesterol had Lp(a) mass >30 mg/dl (the clinically relevant cutpoint), while 59 samples with Lp(a) mass >30 mg/dl did not have detectable Lp(a) cholesterol. Conclusions: Lp(a) cholesterol can be measured in whole plasma without interference from VLDL lipoproteins. The relative clinical merits of measuring Lp(a) cholesterol vs. Lp(a) mass or both in combination deserves investigation.

AB - Objectives: Elevated plasma lipoprotein(a) [Lp(a)] is a significant risk factor for vascular disease. Standardization of Lp(a) mass measurement is complicated by the heterogeneity of apolipoprotein(a) [apo(a)]. We investigated whether Lp(a) cholesterol measurement, which is not influenced by apo(a) size, is a viable alternative to measuring Lp(a) mass. Design and methods: Plasma Lp(a) cholesterol was measured electrophoretically, with and without ultracentrifugation, and results were compared to each other and to immunoturbidimetrically measured Lp(a) mass in 470 subjects. Results: Ultracentrifuged and whole plasma Lp(a) cholesterol levels demonstrated high correlation (R = 0.964). All samples with detectable (≥2.0 mg/dl) Lp(a) cholesterol had Lp(a) mass >30 mg/dl (the clinically relevant cutpoint), while 59 samples with Lp(a) mass >30 mg/dl did not have detectable Lp(a) cholesterol. Conclusions: Lp(a) cholesterol can be measured in whole plasma without interference from VLDL lipoproteins. The relative clinical merits of measuring Lp(a) cholesterol vs. Lp(a) mass or both in combination deserves investigation.

KW - Apolipoprotein(a)

KW - Lipoprotein(a)

KW - Lp(a) cholesterol

KW - Lp(a) mass

KW - Ultracentrifugation

UR - http://www.scopus.com/inward/record.url?scp=2942565904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942565904&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2004.02.001

DO - 10.1016/j.clinbiochem.2004.02.001

M3 - Article

C2 - 15183296

AN - SCOPUS:2942565904

SN - 0009-9120

VL - 37

SP - 481

EP - 488

JO - Clinical Biochemistry

JF - Clinical Biochemistry

IS - 6 SPEC. ISS.

ER -

Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this